Donation

Videos
DREAMM2.jpg'/>dreamm-2-single-agent-belantamab-mafodotin-patients-relapsed-refractory-multiple-myeloma' />What is the DREAMM-2 Trial?DREAMM-2 is an open-label study of belantamab mafodotin. Patients in the trial had actively progressing multiple myeloma that had worsened…
June 10, 2020
Videos
What is the DREAMM-6 trial?The DREAMM-6 trial studies belantamab mafodotin (Bela), a B-cell maturation antigen targeting immunoconjugate. Bela has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated relapsed refractory multiple myeloma (RRMM…
June 10, 2020
Videos
What is the DREAMM-5 platform trial?The DREAMM-5 platform trials studies the single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugates.In this video:Dr. Paul G. Richardson (Dana Farber Cancer Institute — Boston) explains that belantamab…
June 15, 2020
Videos
What is the DREAMM-9 trial?The DREAMM-9 trial is a phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) as the standard of care for transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma patients. Yet, relapse is usually inevitable.In…
June 15, 2020

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.